Erectile dysfunction and diabetes mellitus

Insulin

Volumn 4, Issue 2, 2009, Pages 114-122

  Hatzimouratidis, Konstantinos ^a   Hatzichristou, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

diabetes; epidemiology; erectile dysfunction; pathophysiology; phosphodiesterase inhibitors

Indexed keywords

ANTIANDROGEN; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROLACTIN; PROSTAGLANDIN E1; RECREATIONAL DRUG; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VASOACTIVE AGENT;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; FLUSHING; GLYCEMIC CONTROL; HUMAN; HYPOGONADISM; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; MENTAL STRESS; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARENT COUNSELING; PATHOPHYSIOLOGY; PENILE FIBROSIS; PENIS DISEASE; PENIS ERECTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PREVALENCE; PRIAPISM; PROLACTIN BLOOD LEVEL; RHINITIS; SEX HORMONE DETERMINATION; SEXUAL INTERCOURSE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

EID: 65349128248     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(09)80020-1     Document Type: Article

References (68)

1. Papaharitou S., Athanasiadis L., Nakopoulou E., et al. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: Profiles of 9,536 men calling a helpline. Eur Urol 49 (2006) 557-563
2. Ayta I.A., McKinlay J.B., and Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84 (1999) 50-56
3. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. J Urol 163 (2000) 460-463
4. Laumann E.O., Paik A., and Rosen R.C. Sexual dysfunction in the United States: Prevalence and predictors [published correction appears in JAMA. 1999;281:1174]. JAMA 281 (1999) 537-544
5. Bacon C.G., Hu F.B., Giovannucci E., et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 25 (2002) 1458-1463
6. Laumann E.O., Nicolosi A., Glasser D.B., et al., for the GSSAB Investigators' Group. Sexual problems among women and men aged 40-80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 17 (2005) 39-57
7. Guay A., and Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 4 (2007) 1046-1055
8. Fedele D., Coscelli C., Santeusanio F., et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 21 (1998) 1973-1977
9. Fedele D., Coscelli C., Cucinotta D., et al., for the Diade Study Group. Incidence of erectile dysfunction in Italian men with diabetes. J Urol 166 (2001) 1368-1371
10. Grover S.A., Lowensteyn I., Kaouache M., et al. The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. Arch Intern Med 166 (2006) 213-219
11. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 27 (2006) 2632-2639
12. Kloner R.A. Erectile dysfunction and cardiovascular risk factors. Urol Clin North Am 32 (2005) 397-402
13. Romeo J.H., Seftel A.D., Madhun Z.T., and Aron D.C. Sexual function in men with diabetes type 2: Association with glycemic control. J Urol 163 (2000) 788-791
14. Fonseca V., and Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments?. Am J Cardiol 96 (2005) 13M-18M
15. Esposito K., Giugliano F., Martedì E., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28 (2005) 1201-1203
16. Burke J.P., Jacobson D.J., McGree M.E., et al. Diabetes and sexual dysfunction: Results from the Olmsted County study of urinary symptoms and health status among men. J Urol 177 (2007) 1438-1442
17. Dunsmuir W.D., and Holmes S.A. The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Diabet Med 13 (1996) 700-708
18. Saenz de Tejada I., Angulo J., Cellek S., et al. Physiology of erectile function and pathophysiology of erectile dysfunction. In: Lue T.F., Basson R., Rosen R., et al. (Eds). Sexual Medicine: Sexual Dysfunctions in Men and Women (2004), Health Publications, Paris, France 287-344
19. Saenz de Tejada I., Blanco R., Goldstein I., et al. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am J Physiol 254 (1988) H459-H467
20. Cartledge J.J., Eardley I., and Morrison J.F. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 87 (2001) 394-401
21. Cellek S., Rodrigo J., Lobos E., et al. Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Brit J Pharmacol 128 (1999) 1804-1812
22. Musicki B., and Burnett A.L. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 19 (2007) 129-138
23. Bivalacqua T.J., Usta M.F., Champion H.C., et al. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 24 Suppl 6 (2003) S17-S37
24. Sullivan M.E., Dashwood M.R., Thompson C.S., et al. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: Potential relevance to the pathogenesis of erectile dysfunction. J Urol 158 (1997) 1966-1972
25. Wang H., Eto M., Steers W.D., et al. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem 277 (2002) 30614-30621
26. Bivalacqua T.J., Champion H.C., Usta M.F., et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 101 (2004) 9121-9126
27. Simopoulos D.N., Gibbons S.J., Malysz J., et al. Corporeal structural and vascular micro architecture with X-ray micro computerized tomography in normal and diabetic rabbits: Histo-pathological correlation. J Urol 165 (2001) 1776-1782
28. Wessells H., Teal T.H., Engel K., et al. Fluid shear stress-induced nitric oxide production in human cavernosal endothelial cells: Inhibition by hyperglycemia. BJU Int 97 (2006) 1047-1052
29. Seftel A.D., Vaziri N.D., Ni Z., et al. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition. and possible effect through iNOS or eNOS. Urology 50 (1997) 1016-1026
30. Usta M.F., Bivalacqua T.J., Yang D.Y., et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 170 (2003) 1437-1442
31. Corona G., Mannucci E., Petrone L., et al. Association of hypogo-nadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 18 (2006) 190-197
32. Kapoor D., Aldred H., Clark S., et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 30 (2007) 911-917
33. Laaksonen D.E., Niskanen L., Punnonen K., et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. J Clin Endocrinol Metab. 90 (2005) 712-719
34. Muller M., Grobbee D.E., den Tonkelaar I., et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 90 (2005) 2618-2623
35. Yialamas M.A., Dwyer A.A., Hanley E., et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 92 (2007) 4254-4259
36. Bansal T.C., Guay A.T., Jacobson J., et al. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2 (2005) 96-103
37. Araujo A.B., Johannes C.B., Feldman H.A., et al. Relation between psychosocial risk factors and incident erectile dysfunction: Prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 152 (2000) 533-541
38. Lue T.F., Giuliano F., Montorsi F., et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 1 (2004) 6-23
39. Wespes E., Amar E., Hatzichristou D., et al. EAU Guidelines on erectile dysfunction: An update. Eur Urol. 49 (2006) 806-815
40. Giugliano D., Giugliano F., and Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutr. 9 (2006) 1118-1120
41. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA 291 (2004) 2978-2984
42. Düsing R. Sexual dysfunction in male patients with hypertension: Influence of antihypertensive drugs. Drugs. 65 (2005) 773-786
43. Wassmann S., Hilgers S., Laufs U., et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 22 (2002) 1208-1212
44. Gruenwald I., Shenfeld O., Chen J., et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol. 50 (2006) 134-140
45. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 96 (2005) 85M-93M
46. Rendell M.S., Rajfer J., Wicker P.A., and Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 281 (1999) 421-426
47. Stuckey B.G., Jadzinsky M.N., Murphy L.J., et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: Results of a randomized controlled trial. Diabetes Care. 26 (2003) 279-284
48. Safarinejad M.R. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: A randomized double-blind and placebo-controlled study. J Diabetes Complications. 18 (2004) 205-210
49. Fonseca V., Seftel A., Denne J., and Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia. 47 (2004) 1914-1923
50. Hatzichristou D., Gambla M., Rubio-Aurioles E., et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 25 (2008) 138-146
51. Goldstein I., Young J.M., Fischer J., et al. Vardenafil, a new phos-phodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 26 (2003) 777-783
52. Hatzimouratidis K., and Hatzichristou D.G. A comparative review of the options for treatment of erectile dysfunction: Which treatment for which patient. Drugs. 65 (2005) 1621-1650
53. Price D.E., Cooksey G., Jehu D., et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med. 8 (1991) 964-967
54. Sidi A.A., Becher E.F., Zhang G., and Lewis J.H. Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol. 144 (1990) 1154-1156
55. Padma-Nathan H., Hellstrom W.J., Kaiser F.E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 336 (1997) 1-7
56. Heaton J.P., Lording D., Liu S.N., et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 13 (2001) 317-321
57. Perimenis P., Konstantinopoulos A., Perimeni P.P., et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl. 8 (2006) 219-224
58. Linet O.I., and Ogrinc F.G. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 334 (1996) 873-877
59. Lakin M.M., Montague D.K., VanderBrug Medendorp S., et al. Intracavernous injection therapy: Analysis of results and complications. J Urol. 143 (1990) 1138-1141
60. Tal R., and Mulhall J.P. Intracavernosal injections and fibrosis: Myth or reality. BJU Int. 102 (2008) 525-526
61. Simmons M., and Montague D.K. Penile prosthesis implantation: Past, present and future. Int J Impot Res. 20 (2008) 437-444
62. Henry G.D., and Wilson S.K. Updates in inflatable penile prostheses. Urol Clin North Am. 34 (2007) 535-547
63. Chen Y., Dai Y., and Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother. 9 (2008) 257-266
64. Moore C.R., and Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 8 (2006) 675-684
65. Mulhall J.P., Ahmed A., Branch J., and Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 169 (2003) 1429-1433
66. Carson C.C. Penile prosthesis implantation: Surgical implants in the era of oral medication. Urol Clin North Am. 32 (2005) 503-509
67. Wilson S.K., Carson C.C., Cleves M.A., and Delk II J.R. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 159 (1998) 1537-1539 discussion
68. Wilson S.K., Carson C.C., Cleves M.A., and Delk II J.R. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 159 (1998) 1539-1540